Street Calls of the Week
Jasper Therapeutics, Inc. (NASDAQ:JSPR) President and CEO Ron Martell acquired 41,000 shares of Voting Common Stock on September 22, 2025, at a price of $2.43 per share, for a total transaction value of $99,630. The purchase comes as the stock trades near its 52-week low of $2.27, having declined nearly 89% over the past year. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.
Martell also acquired 41,000 Common Stock Warrants (right to buy) at an exercise price of $2.92. These warrants, which are exercisable beginning March 22, 2026, and expire on March 22, 2030, are linked to 41,000 shares of Voting Common Stock. With a current market capitalization of just $37.87 million, InvestingPro data shows analyst price targets ranging from $4 to $51, suggesting significant potential upside.
Following the transaction, Martell directly owns 74,118 shares of Jasper Therapeutics, Inc. Discover more insights about JSPR and access comprehensive analysis with InvestingPro’s detailed research report, one of 1,400+ available US equity reports providing actionable intelligence for smarter investing decisions.
In other recent news, Jasper Therapeutics announced a public offering expected to raise approximately $30 million in gross proceeds. The offering includes 11,670,707 shares of common stock with accompanying warrants and 675,000 pre-funded warrants. The common warrants are priced at $2.92 per share and will be exercisable starting six months after issuance for a period of four years. In light of this offering, JMP Securities lowered its price target for Jasper Therapeutics to $6, citing significant dilution as a reason for the adjustment. BTIG also adjusted its price target for the company to $7 from $20, maintaining a Buy rating. The company plans to use the proceeds from this offering to further develop briquilimab, an antibody therapy targeting KIT (CD117) for mast cell-driven diseases. These developments follow an update on an investigation into a faulty drug lot for briquilimab. Jasper Therapeutics continues to focus on advancing its clinical-stage biotechnology initiatives amidst these financial adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.